LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia

Background: Acute myelogenous leukemia (AML) is nosocomial with the highest pediatric mortality rates and a relatively poor prognosis. C4.4A(LYPD3) is a tumorigenic and high-glycosylated cell surface protein that has been proven to be linked with the carcinogenic effects in solid tumors, but no hema...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Tingting, Zhang, Yingjie, Yang, Tianqing, He, Qingnan, Zhao, Mingyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963240/
https://www.ncbi.nlm.nih.gov/pubmed/35360840
http://dx.doi.org/10.3389/fgene.2022.795820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963240/
https://www.ncbi.nlm.nih.gov/pubmed/35360840
http://dx.doi.org/10.3389/fgene.2022.795820

Ejemplares similares